Bachem Holding 2026 Forecast | Price, Valuation & Growth

Bachem Holding

SWX:BANB

CHF 66,80

CHF0,00 (0,00%)

66,80 CHF

CHF0,00 (0,00%)

End-of-day quote: 04/03/2026

Bachem Holding Stock Value

Analysts currently rate SWX:BANB as Outperform.

Outperform

Bachem Holding Company Info

EPS Growth 5Y

-16,36%

Market Cap

CHF5,01 B

Long-Term Debt

CHF0,06 B

Quarterly earnings

07/24/2026 (E)

Dividend

CHF0,90

Dividend Yield

1,35%

Founded

1971

Industry

Health Care

Country

Switzerland

Website

Bachem Holding

ISIN Number

CH1176493729

Website

http://www.bachem.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

CHF80,00

19.76%

Last Update: 04/03/2026

Analysts: 10

Highest Price Target CHF110,00

Average Price Target CHF80,00

Lowest Price Target CHF46,00

In the last five quarters, Bachem Holding’s Price Target has fallen from CHF651,64 to CHF616,00 - a -5,47% decrease. Four analysts predict that Bachem Holding’s share price will increase in the coming year, reaching CHF80,00. This would represent an increase of 19,76%.

Top growth stocks in the health care sector (5Y.)

What does Bachem Holding do?

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. The company specializes in providing contract development and manufacturing services (CDMO) to pharmaceutical and biotechnology companies, offering unparalleled expertise in producing these complex molecules. The company has positioned itself as a pioneering entity in developing and implementing innovative manufacturing technologies that enhance produ...

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies.

The company specializes in providing contract development and manufacturing services (CDMO) to pharmaceutical and biotechnology companies, offering unparalleled expertise in producing these complex molecules. The company has positioned itself as a pioneering entity in developing and implementing innovative manufacturing technologies that enhance production efficiency and yield.

Business Segments

The company conducts its operations through distinct business segments that cater to various aspects of API development and manufacturing. Primarily, these segments include Commercial API, CMC Development, and Research & Specialties. Each segment plays a vital role in the overall operations, contributing to the company’s comprehensive service offerings.

The Commercial API segment focuses on the large-scale production of standardized active pharmaceutical ingredients. By maintaining flexibility and scalability within production processes, the company ensures that it is equipped to meet the evolving demands of traditional pharmaceutical markets.

On the other hand, the CMC Development segment emphasizes the importance of creating manufacturing processes and technologies suited for pharmaceutical compounds undergoing clinical trials. These services entail a comprehensive support system that includes investigational product supply, technology transfer, and regulatory compliance, thereby facilitating a seamless pathway from laboratory research to commercial production.

Lastly, the Research & Specialties segment addresses niche requests and pioneering projects that require innovative solutions. This area of business fosters collaboration and experimentation, allowing the company to explore new methodologies and expand its technological capabilities.

Business Strategy

The company’s business strategy is rooted in its commitment to becoming the foremost specialist in the development and production of peptides and oligonucleotides. Central to this strategy is the enhancement of its capabilities and the optimization of its service offerings through continuous innovation and technological advancement.

The company is concurrently developing partnerships and collaborations with key players in the pharmaceutical and biotechnology industries to deliver high-quality APIs that meet stringent regulatory requirements. This collaborative approach significantly amplifies the company’s market reach and allows it to stay attuned to emerging trends and customer needs.

In pursuit of its growth objectives, the company’s business strategy encompasses scaling production capabilities and expanding its global footprint. By investing in infrastructure, the company is well-prepared to meet increasing market demands while ensuring that it continues to deliver the highest quality products and services.

Products and Services

The company specializes in a broad range of products and services centered on peptides and oligonucleotides. The manufactured products mainly include various types of active pharmaceutical ingredients tailored for specific medical applications.

The company’s services extend to include comprehensive contract development and manufacturing services. These services are structured to enhance customer engagement and are critical during various phases of drug development. The company expertise spans across the entire spectrum of producing peptides and oligonucleotides, which covers the scale-up from research to market-ready solutions.

Another area of notable service includes the provision of technical consulting and support, which aids clients in navigating the complex landscape of regulatory requirements and process development. This expertise significantly reduces the operational burden on clients, allowing them to focus on the core aspects of their research and development efforts.

The company is also involved in pioneering the use of new manufacturing technologies that enhance efficiency and yield. The continuous improvement of manufacturing processes is crucial for scaling production and meeting the increased demand for innovative therapies.

Additionally, the company invests significantly in research and development endeavors aimed at discovering novel applications for peptides and oligonucleotides. Collaborative projects with academic institutions and industry leaders support these initiatives, reinforcing the company’s commitment to advancing the scientific facets of its products and services.

Geographical Markets Served

The company operates on a global scale with a strong presence in key geographical markets, including Europe, Asia, and North America. Each market presents unique opportunities and challenges, which the company adeptly navigates to adapt its offerings accordingly. The strategic expansion into various markets enables the company to capitalize on diverse customer bases and optimize its production capacities.

Customers

The company’s customer base primarily consists of pharmaceutical and biotechnology companies engaged in the research and development of innovative therapeutics. The company serves a diverse array of clients, from established industry giants to emerging biotech firms, showcasing its adaptability and expertise in catering to varied customer needs.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing, designed to effectively promote its products and services across various channels. The company focuses on building meaningful relationships with customers through direct engagement, technical consultations, and attendance at industry conferences.

The sales force is trained to understand the complex needs of pharmaceutical and biotech clients, allowing the company to position its offerings strategically. The company also utilizes digital marketing strategies to reach new customers and reinforce its brand presence in the market.

Collaborative partnerships with other industry stakeholders enhance the company’s visibility and credibility within the sector, enabling it to cater effectively to evolving customer needs and market requirements.

History

Bachem Holding AG was founded in 1971.

Bachem Holding Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industries:** - Pharmaceutical industry: approx. 70% - Biotechnology: approx. 20% - Other industries (e.g. research institutions): approx. 10% **TOP 3 markets and their percentage shares:** - USA: approx. 45% - Europe (excluding Switzerland): approx. 30% - Asia: approx. 15...

At which locations are the company’s products manufactured?

**Production sites of Bachem Holding AG:** 1. **Switzerland:** Bubendorf and Vionnaz 2. **USA:** Torrance and Vista, California 3. **Germany:** Weil am Rhein 4. **United Kingdom:** St. Helens Bachem Holding AG is a leading company in peptide production and operates several production facilities wo...

What strategy does Bachem Holding pursue for future growth?

**Revenue growth:** 18% (2024) **Investments in capacity expansion:** 250 million CHF (2024) Bachem Holding AG pursues a growth strategy that strongly focuses on expanding its production capacities and tapping into new markets. In 2024, the company achieved a revenue growth of 18%, driven by the in...

Which raw materials are imported and from which countries?

**Main raw materials:** Amino acids, peptides, solvents **Import countries:** USA, China, India Bachem Holding AG is a leading company in the production of peptides and organic chemicals. The main raw materials imported by Bachem include amino acids and peptides, which are essential components of...

How strong is the company’s competitive advantage?

**Market share:** 20% in the peptide production sector (2024, estimate) **R&D investments:** CHF 150 million (2023) **EBIT margin:** 25% (2023) Bachem Holding AG has a significant competitive advantage in the field of peptide production, as evidenced by its estimated market share of 20%. Th...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 60% (estimated 2025) **Insider Buys/Sells:** No significant transactions in the last quarter (2025) The institutional investor share in Bachem Holding AG is estimated to be around 60%. This indicates a strong interest from institutional investors in the company,...

What percentage market share does Bachem Holding have?

**Market share of Bachem Holding AG:** Estimated 15% (2025) **Main competitors and their market shares:** 1. **Lonza Group AG:** 20% 2. **Catalent, Inc.:** 18% 3. **Thermo Fisher Scientific Inc.:** 17% 4. **Bachem Holding AG:** 15% 5. **Siegfried Holding AG:** 12% 6. **WuXi AppTec:** 10% 7. **Boehr...

Is Bachem Holding stock currently a good investment?

**Revenue Growth:** 18% (2024) **EBITDA Margin:** 30% (2024) **Research and Development Expenses:** 12% of Revenue (2024) Bachem Holding AG recorded strong revenue growth of 18% in 2024, driven by increased demand for its pharmaceutical products and services. The EBITDA margin of 30% demonstrates s...

Does Bachem Holding pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.8% (estimated for 2025) **Dividend History:** Continuous payout for over 10 years Bachem Holding AG has pursued a consistent dividend policy in recent years. The dividend yield is currently around 1.8%, which can be considered moderate compared to other companies in the indu...

New support ticket

Explore

Bachem Holding Stock Value

Bachem Holding Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bachem Holding do?

Bachem Holding Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Bachem Holding Stock Value

Bachem Holding Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bachem Holding do?

Bachem Holding Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.